One of the most effective ways to reduce overtreatment of prostate cancer is to limit its detection in men with low-risk disease. Although many data are currently missing, we foresee a future with reduced prostate-specific antigen (PSA) testing in men selected through baseline PSA values or genetic predisposition.
Then selective biopsy using multiparametric magnetic resonance imaging and longitudinal biomarkers will play a role.
European urology. 2016 Feb 22 [Epub ahead of print]
Giorgio Gandaglia, Alberto Briganti, Nicola Fossati, Andrea Salonia, Alexandre Mottrie, James Catto, Francesco Montorsi
Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy; OLV Vattikuti Robotic Surgery Institute, Melle, Belgium., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy., OLV Vattikuti Robotic Surgery Institute, Melle, Belgium., Academic Urology Unit and Institute for Cancer Studies, The Medical School, University of Sheffield, Sheffield, UK., Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.